Results 291 to 300 of about 97,155 (350)

Considerations for drug trials in hypertrophic cardiomyopathy

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant   +17 more
wiley   +1 more source

CT Imaging for Valvular Interventions. [PDF]

open access: yesStruct Heart
Wang DD   +5 more
europepmc   +1 more source

Reframing the role of glucagon‐like peptide 1 receptor agonists in cardiovascular medicine

open access: yes
ESC Heart Failure, Volume 12, Issue 2, Page 923-926, April 2025.
Riccardo M. Inciardi   +3 more
wiley   +1 more source

CMR Left Ventricular Filling Pressure Exhibits Strong Haemodynamic Relevance and Outperforms Echocardiography in Multimodal Heart Failure Assessment. [PDF]

open access: yesJ Cardiovasc Dev Dis
Bana A   +17 more
europepmc   +1 more source

Pathophysiological mechanisms of Postural Orthostatic Tachycardia Syndrome analyzed by means of hemodynamics. [PDF]

open access: yesPLoS One
Wei L   +9 more
europepmc   +1 more source

Two causes of COVID‐19‐related myocardial injury‐associated cardiogenic shock: Myocarditis and microvascular thrombosis

open access: yes
ESC Heart Failure, Volume 12, Issue 2, Page 1514-1522, April 2025.
Takamasa Iwai   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy